Abstract: This application describes compositions of receptor inhibitors, including typical antipsychotic agents, for example haloperidol, and methods of use for treating clinical signs or symptoms of Parkinson's disease. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in Parkinson's disease as a means of alleviating the clinical signs or symptoms of Parkinson's disease.

Abstract: This application describes compositions of receptor inhibitors, including antipsychotic agents, for example haloperidol, and methods of use for alleviating clinical depression, improving cognition and/or treating other syndromes, conditions or diseases for which anti-depressant agents are prescribed. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in depression and/or cognition as a means of alleviating clinical depression or improving cognition.

Abstract: This application describes compositions of receptor inhibitors, including antipsychotic agents, for example haloperidol, and methods of use for alleviating clinical depression, improving cognition and/or treating other syndromes, conditions or diseases for which anti-depressant agents are prescribed. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in depression and/or cognition as a means of alleviating clinical depression or improving cognition.

Abstract: This application describes compositions of receptor inhibitors, including typical antipsychotic agents, for example haloperidol, and methods of use for treating clinical signs or symptoms of Parkinson's disease. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in Parkinson's disease as a means of alleviating the clinical signs or symptoms of Parkinson's disease.

Abstract: This application describes compositions of receptor inhibitors, including antipsychotic agents, for example haloperidol, and methods of use for alleviating clinical depression, improving cognition and/or treating other syndromes, conditions or diseases for which anti-depressant agents are prescribed. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in depression and/or cognition as a means of alleviating clinical depression or improving cognition.

Abstract: The present invention relates to a central nervous system-acting substituted butyrophenones. These compounds are useful in antipsychotic medications for psychosis, including schizophrenia, but especially for L-DOPA-induced psychosis, while having low or no risk of eliciting extrapyramidal side effects, hyperprolactinemia or tardive dyskinesia.

Abstract: This application describes a method for identifying dopamine supersensitivity using radioactive (+)PHNO. The method involves determining the specific binding of radioactive (+)PHNO in the subject's brain. An increase in the specific binding of radioactive (+)PHNO in the subject compared to a control indicates that the subject is in a state of dopamine supersensitivity. The extent of dopamine supersensitivity can be used to assess, treat and/or follow the progress of any dopamine-related disorder.

Abstract: This application describes fluorinated (+)PHNO and analogs thereof, including radiolabeled analogs, compositions comprising these compounds and methods of using these compounds, for example, for identifying dopamine supersensitivity.

Abstract: This application describes a method for identifying dopamine supersensitivity using radioactive (+)PHNO. The method involves determining the specific binding of radioactive (+)PHNO is the subject's brain. An increase in the specific binding of radioactive (+)PHNO in the subject compared to a control indicates that the subject is in a state of dopamine supersensitivity. The extent of dopamine supersensitivity can be used to assess, treat and/or follow the progress of any dopamine-related disorder.

Abstract: This application relates to a method for treating various aspects of alcoholism, including alcohol craving and relapse into alcoholism, by the administration of an effective amount of gaseous anaesthesia to a deep surgical anaesthesia. The method can be applied for the alleviation of addiction and craving associated with amphetamine use, and for the alleviation of psychosis in schizophrenia and the alleviation of psychosis in Alzheimer's disease. In addition, the state of addiction or the state of psychosis, or the state of alcohol withdrawal can be monitored in animal tissue in vitro or in humans in vivo by measuring the density of the high-affinity states of the dopamine D2 receptors in the striatum or other brains regions containing these receptors which are elevated in these conditions.

Abstract: Methods and kits for determining susceptibility of a patient to neuropsychiatric disorders are described. The method involves analyzing a sample comprising nucleic acids from a patient for a polymorphism of the Nogo gene.